Fairvoy Private Wealth LLC Acquires New Shares in Halozyme Therapeutics, Inc. $HALO

Fairvoy Private Wealth LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 10,892 shares of the biopharmaceutical company’s stock, valued at approximately $1,202,000.

Other institutional investors have also added to or reduced their stakes in the company. CoreCap Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 98.0% in the 3rd quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 150 shares in the last quarter. MidFirst Bank bought a new position in shares of Halozyme Therapeutics during the second quarter valued at $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Halozyme Therapeutics during the second quarter valued at $28,000. Quantbot Technologies LP bought a new position in shares of Halozyme Therapeutics during the second quarter valued at $30,000. Finally, Mather Group LLC. lifted its holdings in shares of Halozyme Therapeutics by 48.9% during the third quarter. Mather Group LLC. now owns 414 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 136 shares in the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the sale, the director owned 40,418 shares of the company’s stock, valued at $4,154,970.40. The trade was a 3.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total transaction of $2,148,600.00. Following the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $82,482,605.40. The trade was a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 125,852 shares of company stock worth $13,538,046 in the last 90 days. 2.50% of the stock is currently owned by insiders.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO traded up $0.66 during trading on Monday, hitting $122.50. The company’s stock had a trading volume of 1,894,130 shares, compared to its average volume of 1,944,203. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The firm has a market cap of $13.90 billion, a price-to-earnings ratio of 36.57, a P/E/G ratio of 0.46 and a beta of 0.88. The company has a 50-day moving average of $109.06 and a 200-day moving average of $85.08. Halozyme Therapeutics, Inc. has a 12 month low of $61.22 and a 12 month high of $123.60.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. During the same period in the previous year, the business posted $1.54 earnings per share. The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 8.31 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. HC Wainwright increased their price objective on Halozyme Therapeutics from $115.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, October 7th. Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Stifel Nicolaus set a $130.00 price target on shares of Halozyme Therapeutics in a report on Friday. Finally, Wells Fargo & Company raised their price target on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $99.55.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.